<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8265">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950104</url>
  </required_header>
  <id_info>
    <org_study_id>IVISEV-005VINCI</org_study_id>
    <nct_id>NCT01950104</nct_id>
  </id_info>
  <brief_title>Day 3 Embryo Biopsy Versus Blastocyst Biopsy in PGS Cases</brief_title>
  <acronym>VINCI</acronym>
  <official_title>Comparative Study Between Day 3 Embryo Biopsy and Blastocyst Biopsy in Preimplantation Genetic Screening Cases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Sevilla</source>
  <oversight_info>
    <authority>Spain: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preimplantation genetic diagnosis (PGS) is a technique that allow us to improve the results
      of assisted reproduction techniques through the selection of embryos free of chromosomal
      abnormalities.

      At present, it has not been proved that the usage of PGS really improves the live birth rate
      in IVF cycles. However, it has been stated that the reason of not having better results when
      using PGS is that the methodology applied is not adequate.

      Several authors propose that the optimal methodology for PGS includes the application of
      comparative genomic hybridization (CGH) arrays for genetic testing and carrying out embryo
      biopsy at the blastocyst stage. Nevertheless, most IVF centres still applies the day 3
      embryo biopsy as a daily routine. Despite this fact, there is a gradual transition towards
      the usage of blastocyst-stage biopsy instead of day 3 biopsy.

      The purpose of this clinical study is analysing the results of the IVF cycles with embryo
      biopsy for PGS. Live birth rates and other parameters as the pregnancy and implantation
      rates together with embryo quality will be analysed and compared between two groups of
      patients undergoing IVF cycles with PGS. In one group the biopsy will be applied in day 3 of
      the embryo development, while in the other group the embryo biopsy will be fulfilled at the
      blastocyst stage.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>20 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Day 3 embryo quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>20 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Infertility</condition>
  <condition>Embryo Biopsy</condition>
  <arm_group>
    <arm_group_label>Day 3 embryo biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Embryo biopsy is applied at day 3 of the embryo development</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blastocyst biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Day 3 embryo biopsy</intervention_name>
    <description>Embryo biopsy is applied at day 3 of the embryo development.</description>
    <arm_group_label>Day 3 embryo biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blastocyst biopsy</intervention_name>
    <description>Embryo biopsy is applied at the blastocyst stage of the embryo development</description>
    <arm_group_label>Blastocyst biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients under 49 years undergoing IVF cycles with PGS for one of the following reasons:

          -  Advanced maternal age

          -  Recurrent implantation failure

          -  Recurrent abortion

          -  Severe male-factor infertility

        Exclusion Criteria:

          -  Not being able to sign the informed consent to participate in the study

          -  Patients undergoing preimplantation genetic diagnosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Victor Blasco, MSc</last_name>
    <phone>+34 954286274</phone>
    <email>victor.blasco@ivi.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>IVI Sevilla</name>
      <address>
        <city>Seville</city>
        <zip>41006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Blasco, MSc</last_name>
      <phone>+34 954286274</phone>
      <email>victor.blasco@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Victor Blasco, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Prados, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Fernandez-Sanchez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 26, 2013</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Embryo biopsy</keyword>
  <keyword>Blastocyst stage</keyword>
  <keyword>Day 3</keyword>
  <keyword>Preimplantation genetic screening</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
